IGI Laboratories Announces 4th Quarter 2012 and Year End 2012 Results

IGI Laboratories Announces 4 th Quarter 2012 and Year End 2012 Results

BUENA, N.J.--(BUSINESS WIRE)-- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the fourth quarter and year ended December 31, 2012.

Fourth Quarter 2012 Highlights vs. 2011

  • Total Revenues of $2.3 million, increase of 10% over same quarter in 2011
  • Invested in the infrastructure of our commercialization strategy and successfully launched the first ever IGI label generic topical pharmaceutical products
  • Raised approximately $2.0 million in cash through the sale of treasury stock to fund the purchase of the topical pharmaceutical product econazole nitrate cream 1%
  • Net loss was $1.2 million and $0.5 million for the fourth quarter of 2012 and 2011
  • Net loss included research and development costs of $1.1 and $0.6 million in 2012 and 2011
  • Increase in research and development costs in the fourth quarter of 2012 over the same quarter last year due to additional costs related to approximately $0.3 million of Generic Drug User Fee Amendments of 2012 (GDUFA) fees required by the US FDA and $0.3 million of costs related to clinical studies

Year to Date 2012 Highlights vs. 2011

  • Total Revenues of $8.6 million in 2012, an increase of 10% over 2011
  • Net loss was $3.9 million in 2012 as compared to a net loss of $3.0 million in 2011
  • Net loss included research and development costs of $2.8 million and $2.2 million in 2012 and 2011
  • IGI has filed nine Abbreviated New Drug Applications (ANDAs) to date

IGI's President and Chief Executive Officer, Jason Grenfell-Gardner, stated, "I am extremely pleased with the progress IGI made in 2012. We launched the first ever IGI labeled topical pharmaceutical product; we filed five ANDAs with the US FDA, three for our own pipeline; we hired a proven leader as our head of research and development; and we raised over $2.0 million through the sale of treasury stock that we believe will enable us to accelerate revenue growth in 2013 with the purchase of econazole nitrate cream." Mr. Grenfell-Gardner continued, "That is an impressive list of accomplishments in the second half of 2012. We have an even longer list of goals for 2013. We target to at least double our 2012 total revenue, achieve profitability and file at least another six ANDAs. We believe that IGI has an exciting year ahead and I look forward to leading our team as we continue on our path to be a leader in the generic topical prescription drug market."

   
IGI LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the three months ended December 31, 2012 and 2011
(in thousands, except shares and per share information)
 

Three months ended December 31,

  2012     2011  
Revenues:
Product sales, net $ 1,711 $ 1,699
Research and development income 563 383
Other revenue   34     13  
Total revenues 2,308 2,095
 
Costs and Expenses:
Cost of sales 1,516 1,433
Selling, general and administrative expenses 824 778
Product development and research expenses   1,099     578  
Total costs and expenses   3,439     2,789  
Operating loss (1,131 ) (694 )
Interest expense (234 ) (73 )
Interest and other income, net   (1 )   2  
Loss before benefit from income taxes (1,366 ) (765 )
Benefit from income taxes   184     226  
 
Net loss $ (1,182 ) $ (539 )
 
Basic and diluted loss per common share $ (.03 ) $ (.01 )
Weighted average shares of common stock outstanding
Basic and diluted   40,608,169     39,498,096  
   
IGI LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the years ended December 31, 2012 and 2011
(in thousands, except shares and per share information)
 
  2012     2011  
Revenues:
Product sales, net $ 6,545 $ 6,729
Research and development income 1,931 921
Licensing, royalty and other income   87     156  
Total revenues 8,563 7,806
 
Costs and Expenses:
Cost of sales 5,787 5,546
Selling, general and administrative expenses 3,078 3,078
Product development and research expenses   2,834     2,151  
Total costs and expenses   11,699     10,775  
Operating loss (3,136 ) (2,969 )
Interest expense (962 ) (281 )
Interest and other income(expense), net   (13 )   17  
Loss before benefit from income taxes (4,111 ) (3,233 )
Benefit from income taxes   184     226  
 
Net loss $ (3,927 ) $ (3,007 )
Basic and diluted loss per common share $ (.10 ) $ (.08 )
 
Weighted average shares of common stock outstanding
Basic and diluted   39,786,446     39,448,706  
   
IGI LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the years ended December 31, 2012 and 2011
(in thousands)
 
  2012     2011  

Cash flows from operating activities:

Net loss $ (3,927 ) $ (3,007 )
Non-cash expenses 1,844 1,117
Changes in operating assets and liabilities   (290 ) (504 )
 
Net cash used in operating activities (2,373 ) (2,394 )
 
Net cash used in investing activities (342 ) (350 )
 
Net cash provided by financing activities   2,337   542  
 
Net decrease in cash and cash equivalents (378 ) (2,202 )
Cash and cash equivalents at beginning of year   2,914     5,116  
Cash and cash equivalents at end of year $ 2,536   $ 2,914  
   
IGI LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share information)
 
December 31, December 31,
2012 2011
ASSETS
Current assets:
Cash and cash equivalents $ 2,536 $ 2,914
Accounts receivable, net 1,577 1,208
 
Inventories 1,773 1,195
Prepaid expenses and other receivables   253     369  
Total current assets 6,139 5,686
Property, plant and equipment, net 2,691 2,800
Restricted cash, long term 54 54
License fee, net 300 400
Debt issuance costs, net 100 639
Other   143     57  
Total assets $ 9,427   $ 9,636  
 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 1,091 $ 629
Accrued expenses 820 611
Deferred income, current 48 38
Capital lease obligation, current   17     38  
Total current liabilities 1,976 1,316
 
Note payable 1,000 -
Note payable, related party - 500
Deferred income, long term 20 25
Capital lease obligation, long term   4     30  
Total liabilities   3,000     1,871  
 
Commitments and contingencies
 
Stockholders' equity:

Series A Convertible Preferred stock, liquidation preference - $500,000 at December 31, 2012 and December 31, 2011

500 500

Series C Convertible Preferred stock, liquidation preference - $1,764,240 at December 31, 2012 and $1,686,527 at December 31, 2011

1,517

1,517

Common stock 446 415
Additional paid-in capital 47,409 46,246
Accumulated deficit (43,445 ) (39,518 )
Less treasury stock, 1,965,740 common shares at cost at December 31, 2011   -     (1,395 )
Total stockholders' equity   6,427     7,765  
Total liabilities and stockholders' equity $ 9,427   $ 9,636  
 

About IGI Laboratories, Inc.

IGI Laboratories is a developer and manufacturer of topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.

IGI Laboratories, Inc. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as " will," "believe", "target", "possible," "one time," "provides an opportunity," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Actual results may differ materially from these expectations due to changes in global political, economic, business, competitive, market and regulatory factors or IGI Laboratories, Inc.'s ability to implement business plans and strategies. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.



IGI Laboratoires, Inc.
Jenniffer Collins, 856-697-1441
www.igilabs.com

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:

The article IGI Laboratories Announces 4th Quarter 2012 and Year End 2012 Results originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investment Strategies

What's your investing game plan?

View Course »

What is Short Selling?

Make a profit when stocks prices fall.

View Course »

Add a Comment

*0 / 3000 Character Maximum